dc.contributor.author | CIFTCI, Rumeysa | |
dc.contributor.author | Pala-Kara, Zeliha | |
dc.contributor.author | Kaytan-Saglam, Esra | |
dc.contributor.author | PILANCI, Kezban Nur | |
dc.contributor.author | Okyar, Alper | |
dc.contributor.author | Saglam, Sezer | |
dc.contributor.author | YÜCEL, Serap | |
dc.contributor.author | Ordu, Cetin | |
dc.contributor.author | Namal, Esat | |
dc.contributor.author | Iner-Koksal, Ulkuhan | |
dc.date.accessioned | 2021-03-06T21:18:43Z | |
dc.date.available | 2021-03-06T21:18:43Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | PILANCI K. N. , Saglam S., Okyar A., YÜCEL S., Pala-Kara Z., Ordu C., Namal E., CIFTCI R., Iner-Koksal U., Kaytan-Saglam E., "Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study", CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.78, ss.143-150, 2016 | |
dc.identifier.issn | 0344-5704 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_fe1b2996-efcc-4aa1-9e19-3257e2b3502b | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/166200 | |
dc.identifier.uri | https://doi.org/10.1007/s00280-016-3067-x | |
dc.description.abstract | The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer. | |
dc.language.iso | eng | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Eczacılık | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Temel Bilimler | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ONKOLOJİ | |
dc.title | Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study | |
dc.type | Makale | |
dc.relation.journal | CANCER CHEMOTHERAPY AND PHARMACOLOGY | |
dc.contributor.department | İstanbul Bilim Üniversitesi , , | |
dc.identifier.volume | 78 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | 143 | |
dc.identifier.endpage | 150 | |
dc.contributor.firstauthorID | 70458 | |